Evidence map›Paper›PMID 25469036›Full record

ArticleWorld journal of gastroenterology2014

Glytan decreases portal pressure via mesentery vasoconstriction in portal hypertensive rats.

Qing-Hong Du, Lin Han, Jun-Jie Jiang, Ya Xu, Wei-Hong Li, Peng-Tao Li, Xin-Yue Wang, Xu Jia

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact, top 91% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Gan Shen Fu Fang ameliorates liver fibrosisWorld journal of gastroenterology · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Qing-Hong DuQing-Hong Du, Lin Han, Ya Xu, Wei-Hong Li, Xu Jia, School of Fundamental Medicine, Beijing University of Chinese Medicine, Beijing 100029, China.
Lin HanQing-Hong Du, Lin Han, Ya Xu, Wei-Hong Li, Xu Jia, School of Fundamental Medicine, Beijing University of Chinese Medicine, Beijing 100029, China.
Jun-Jie JiangQing-Hong Du, Lin Han, Ya Xu, Wei-Hong Li, Xu Jia, School of Fundamental Medicine, Beijing University of Chinese Medicine, Beijing 100029, China.
Ya XuQing-Hong Du, Lin Han, Ya Xu, Wei-Hong Li, Xu Jia, School of Fundamental Medicine, Beijing University of Chinese Medicine, Beijing 100029, China.
Wei-Hong LiQing-Hong Du, Lin Han, Ya Xu, Wei-Hong Li, Xu Jia, School of Fundamental Medicine, Beijing University of Chinese Medicine, Beijing 100029, China.
Peng-Tao LiQing-Hong Du, Lin Han, Ya Xu, Wei-Hong Li, Xu Jia, School of Fundamental Medicine, Beijing University of Chinese Medicine, Beijing 100029, China.
Xin-Yue WangQing-Hong Du, Lin Han, Ya Xu, Wei-Hong Li, Xu Jia, School of Fundamental Medicine, Beijing University of Chinese Medicine, Beijing 100029, China.
Xu JiaQing-Hong Du, Lin Han, Ya Xu, Wei-Hong Li, Xu Jia, School of Fundamental Medicine, Beijing University of Chinese Medicine, Beijing 100029, China.
World Wide Web Consortium · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo investigate the effects of Glytan on splanchnic hemodynamics and its reduction of portal pressure in portal hypertensive rats.

methodsGlytan (Ganluotong in Chinese), is composed of salvianolic acid B and diammonium glycyrrhizinate. Portal hypertension (PHT) was induced in the rats by common bile duct ligation (BDL). Hemodynamic studies were performed using the colored microsphere method. Radioimmunoassay (RIA) was used to determine endothelin (ET)-1 levels in the mesenteric circulation. Western blotting methods were used to investigate the effect of Glytan on ET A receptor (ETAR), ET B receptor (ETBR), endothelial NO synthase (eNOS), G-protein-coupled receptor kinase (GRK)2, and β-arrestin 2 expression in the mesentery. The mRNA of ETAR and ETBR was determined using real-time polymerase chain reaction.

resultsTreatment with Glytan reduced portal pressure (PP) and portal territory blood flow (PTBF) and increased both mean arterial pressure (MAP) and splanchnic vascular resistance (SVR). Especially at 4 wk, PP decreased by about 40%, while MAP increased by 13%, SVR increased by 12%, and PTBF decreased by about 21%. The effect of blood flow reduction was greatest in the mesentery (about 33%) at 4 wk. The mesenteric circulation ET-1 levels of BDL rats were lower and negatively correlated with PP at 4 wk. Glytan can increase mesenteric ET-1 content and inhibit ETBR, eNOS, GRK2, and β-arrestin 2 expression in the mesentery. Moreover, Glytan showed no effect on the expression of ETAR protein and mRNA.

conclusionThe decreased PP and PTBF observed after Glytan treatment were related to increased mesenteric vasoconstriction and increased receptor sensitivity to vasoconstrictor.

Indexed as

AnimalsBenzofuransBlood Flow VelocityDisease Models, AnimalDrugs, Chinese HerbalEndothelin-1Endothelin B Receptor AntagonistsGlycyrrhetinic AcidG-Protein-Coupled Receptor Kinase 2Hypertension, PortalMaleMesenteryNitric Oxide Synthase Type IIIPortal PressureProtein Kinase InhibitorsRats, Sprague-DawleyBenzofuransDrugs, Chinese HerbalEndothelin-1Endothelin B Receptor AntagonistsganluotongGlycyrrhetinic AcidG-Protein-Coupled Receptor Kinase 2Grk2 protein, ratNitric Oxide Synthase Type IIINos3 protein, ratProtein Kinase InhibitorsReceptor, Endothelin BVasoconstrictor AgentsEndothelin-1GlytanHemodynamicsMesenteryPortal hypertensionReceptorSensitivity

Identifiers

PMID25469036
PMCPMC4248211
OpenAlexW2057557599

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.